SEC Form SC 13G/A filed by Agilent Technologies Inc. (Amendment)
$A
Biotechnology: Laboratory Analytical Instruments
Industrials
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/9/2026 | $135.00 | Hold | Jefferies |
| 6/26/2026 | $155.00 | Outperform | Bernstein |
| 6/11/2026 | $150.00 | Neutral | Piper Sandler |
| 5/28/2026 | $145.00 | Neutral → Buy | BofA Securities |
| 5/27/2026 | $153.00 | Outperform | RBC Capital Mkts |
| 1/20/2026 | $180.00 | Buy | HSBC Securities |
| 1/5/2026 | $160.00 | In-line → Outperform | Evercore ISI |
| 12/15/2025 | $165.00 | Equal Weight → Overweight | Barclays |
4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
Test enables identification of patients whose tumors express PD-L1 and who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® Agilent Technologies Inc. (NYSE:A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb’s PD‑1‑targeted immunotherapeutic agents. PD-L1 IHC 28-8 pharmDx is approved for exclusi
Agilent Technologies Inc. (NYSE:A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides, and conjugated therapeutics. Applications such as aggregate characterization, molecular weight confirmation and size distribution analysis remain essential for evaluating product quality, stability and performance, while drug-to-antibody
Simplifying label-free imaging analysis for more confident real-time cell analysis Agilent Technologies Inc. (NYSE:A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to gain imaging and impedance insights from the same cells in the same experiment with greater speed and confidence. This streamlined, integrated approach i
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
3 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
SD - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
Jefferies resumed coverage of Agilent with a rating of Hold and set a new price target of $135.00
Bernstein resumed coverage of Agilent with a rating of Outperform and set a new price target of $155.00
Piper Sandler initiated coverage of Agilent with a rating of Neutral and set a new price target of $150.00
Agilent Technologies Inc. (NYSE:A) today announced the appointment of Michael Buckner as chief legal officer, effective today. Buckner brings nearly three decades of experience as a senior global legal executive, with a proven track record of building and leading high-performing teams and deep expertise in complex transactions and regulatory environments. "We are thrilled to welcome Michael to the Agilent team," said Padraig McDonnell, Agilent president and CEO. "His experience leading global legal organizations, combined with his expertise across governance, compliance and regulatory matters, will play a key role as we continue to advance our strategy and deliver for our customers and
Agilent Technologies Inc. (NYSE:A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand for more integrated approaches across the cancer research continuum. Among the technologies featured is the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation series of cell imaging and multimode micropla
Agilent Technologies Inc. (NYSE:A) today announced the appointment of Adam S. Elinoff as chief financial officer, effective Nov. 17. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027719923/en/Adam S. Elinoff, Chief Financial Officer, Agilent Technologies Elinoff brings two decades of financial experience spanning corporate finance, investor relations, strategy and business transformation, and has a proven record of driving enterprise-wide transformations, optimizing financial operations and scaling global capabilities. He joins Agilent from Amgen, a worldwide pioneer in biotechnology, where he advanced through a series of
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
Delivers strong Q2 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS(4) guidance on continued operational momentum Second-quarter fiscal year 2026 Revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core(1) compared with the second quarter of 2025. GAAP operating margin of 21.7%; non-GAAP operating margin(2) of 26.4% expanded by 130 basis points year-over-year and 180 basis points sequentially. GAAP net income of $339 million; earnings per share (EPS) of $1.20, an increase of 60% from the second quarter of 2025. Non-GAAP net income(3) of $423 million; non-GAAP EPS(3) of $1.49, an incre
Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on July 22, 2026, to all shareholders of record as of the close of business on June 30, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide tru
New indices deliver transparent, comprehensive access to Australian equities for benchmarking and investment applicationsNEW YORK and SYDNEY, April 28, 2026 /PRNewswire/ -- Bloomberg today announced the launch of the new Bloomberg Australia Domestic Equity Indices. The indices are designed to provide broad and investable exposure to Australian equities for benchmarking, asset allocation, and creation of financial products for both institutional and retail investors. "The launch of our Australia Domestic Equity Indices represents a natural evolution of our offering, building on a